Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans

被引:72
作者
Allabi, AC
Gala, JL
Horsmans, Y
Babaoglu, MO
Bozkurt, A
Heusterspreute, M
Yasar, U
机构
[1] Catholic Univ Louvain, St Luc Univ Hosp, Ctr Human Genet, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, St Luc Univ Hosp, Clin Pharmacol Unit, B-1200 Brussels, Belgium
[3] Hacettepe Univ, Fac Med, Dept Pharmacol, TR-06100 Ankara, Turkey
关键词
D O I
10.1016/j.clpt.2004.04.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Aim: Previous data indicate that the urinary losartan/E-3174 ratio is a marker for cytochrome P450 (CYP) 2C9 activity in vivo. The functional impact of CYP2C9(star)5, (star)6, (star)8, and (star)11 polymorphisms in vivo has not been investigated previously in humans. Methods: A single oral dose of losartan (25 mg) was given to 19 Beninese subjects with CYP2C9(star)1/(star)1 (n = 9), (star)1/(star)5 (n = 1), (star)1/(star)6 (n = 1), (star)1/(star)8 (n = 2), (star)1/(star)11 (n = 3), (star)5/(star)6 (n = 1), (star)5/(star)8 (n = 1), and (star)8/(star)11 (n = 1) genotypes. Concentrations of losartan and its active metabolite E-3174 were determined in urine from 0 to 8 hours by HPLC. The losartan/E-3174 metabolic ratio was used as a measure of losartan oxidation in vivo. Results: The urinary losartan/E-3174 ratio in the various genotypes was as follows: 1.85 +/- 2.4 (mean +/- SD) for CYP2C9(star)1/(star)1, 14.6 for CYP2C9(star)1/star5, 4.2 for CYP2C9(star)1/(star)6, 188 for CYP2C9(star)5/(star)6, 11.6 for CYP2C9(star)5/(star)8, 0.44 +/- 0.13 (mean +/- SD) for CYP2C9(star)1/(star)8, 2.2 for CYP2C9(star)8/(star)11, and 5.72 +/- 4.5 (mean +/- SD) for CYP2C9(star)1/(star)11. Compared with the CYP2C9(star)1/(star)1 genotypes, the losartan/E-3174 ratio was significantly different in the CYP2C9(star)5 allele carriers (CYP2C9(star)1/(star)5, CYP2C9(star)5/(star)8, and CYP2C9(star)5/(star)6 genotypes) (P = .01, Mann-Whitney) but was not different in CYP2C9(star)1/(star)8 (P = .16) and CYP2C9(star)1/(star)11 (P = .11) carriers. The urinary losartan/E-3174 ratio of the single CYP2C9(star)1/(star)6 subject was higher than the 95% confidence interval of the mean of the CYP2C9(star)1/(star)1 group (0.0-3.7), whereas the metabolic ratio of the CYP2C9(star)8/(star)11 carrier was inside the 95% confidence interval of the means of the CYP2C9(star)1/(star)1 and CYP2C9(star)1/(star)11 groups (0.0-18). Conclusions: The CYP2C9(star)5 and (star)6 alleles are associated with decreased enzyme activity in vivo compared with the wild-type variant, whereas the CYP2C9(star)8 and (star)11 variants did not appear to have large in vivo effects.
引用
收藏
页码:113 / 118
页数:6
相关论文
共 30 条
  • [1] Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
    Allabi, AC
    Gala, JL
    Desager, JP
    Heusterspreute, M
    Horsmans, Y
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) : 653 - 657
  • [2] Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
  • [3] Severe phenytoin intoxication in a subject homozygous for CYP2C9*3
    Brandolese, R
    Scordo, MG
    Spina, E
    Gusella, M
    Padrini, R
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (04) : 391 - 394
  • [4] Phenytoin metabolic ratio:: a putative marker of CYP2C9 activity in vivo
    Caraco, Y
    Muszkat, M
    Wood, AJJ
    [J]. PHARMACOGENETICS, 2001, 11 (07): : 587 - 596
  • [5] Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
    Chang, M
    Dahl, ML
    Tybring, G
    Gotharson, E
    Bertilsson, L
    [J]. PHARMACOGENETICS, 1995, 5 (06): : 358 - 363
  • [6] The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes
    Christensen, M
    Andersson, K
    Dalén, P
    Mirghani, RA
    Muirhead, GJ
    Nordmark, A
    Tybring, G
    Wahlberg, A
    Yasar, Ü
    Bertilsson, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) : 517 - 528
  • [7] Pharmacogenetics of oral anticoagulants
    Daly, AK
    King, BP
    [J]. PHARMACOGENETICS, 2003, 13 (05): : 247 - 252
  • [8] Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
    Dickmann, LJ
    Rettie, AE
    Kneller, MB
    Kim, RB
    Wood, AJJ
    Stein, CM
    Wilkinson, GR
    Schwarz, UI
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (02) : 382 - 387
  • [9] GRIESE EU, 1998, PHARMACOGENETICS, V8, P5
  • [10] Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
    Griskevicius, L
    Yasar, Ü
    Sandberg, M
    Hidestrand, M
    Eliasson, E
    Tybring, G
    Hassan, M
    Dahl, ML
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (02) : 103 - 109